Epigenetic regulation of lymphatic development

淋巴管发育的表观遗传调控

基本信息

项目摘要

PROJECT SUMMARY / ABSTRACT: Congenital or neonatal accumulation of chyle in the pleural space is the most common cause of pleural effusion affecting 1 in 10,000 births with mortality rates between 20-60%. Neonatal patients with a spontaneous accumulation of chyle frequently exhibit bilateral pleural effusion, severe respiratory distress, tachypnea, and cyanosis, suggesting the mechanical effect of compression on lung compliance and impairment of gas exchange in alveoli. Although Dr. Bartloet established accumulation of chyle in the pleural space as a lymphatic anomaly in 1633, the mechanism for their formation and treatment have not been fully defined. Recent studies reveal the requirement of prenatal lymphatic function to drain pleural fluid and promote the inflation of lungs at birth, which is required for viability. To accomplish this, an extensive network of lymphatic vessels within the pleura, the intercostal space, the perivascular spaces of arterioles and venules, and the connective tissue of the terminal and respiratory bronchioles maintain fluid homeostasis and promote effective gas exchange. Abnormal dilation of these lymphatic vessels, known as lymphangiectasia, is frequently associated with neonatal chylous effusion, immature lungs, and severe respiratory distress with mortality. Even though Dr. Rudolf Virchow described neonatal pulmonary lymphangiectasia as early as 1856, the underlying causal etiology and treatment options remain elusive. Our preliminary studies identify an unexpected causal link between pathological MAPK activation and lymphangiectasia in mice and humans. Pathological activation of lymphatic MAPK causes severe pulmonary lymphangiectasia, accumulation of chyle in the pleural space, and complete lethality. Preliminary analyses of human pathological tissue samples from patients diagnosed with lymphangiectasia revealed sustained MAPK activation within lymphatic endothelial cells and recapitulated the murine phenotype. Mechanistically, the genome-wide phosphorylated MAPK occupancy screen revealed direct regulation of an evolutionarily conserved genetic program required for lymphatic vessel structure and function. This research program aims to identify how the MAPK signaling pathway establishes and maintains a specific transcriptional program for lymphatic vessel development. In addition, proposed studies will identify the mechanisms by which specific kinases and transcription factors interact to regulate the chromatin recruitment of MAPK within developing pulmonary lymphatic vasculature. The set of proposed studies has broad significance for understanding how signaling pathways intersect with chromatin-modifying transcription factors to regulate the development of organ-specific lymphatic vasculature and could be highly applicable to the entire field of congenital vascular diseases.
项目摘要/摘要: 先天性或新生儿乳糜液在胸腔积聚是胸腔积液最常见的原因。 影响10000名新生儿中的1名,死亡率在20%-60%之间。新生儿自发性心绞痛 乳糜聚积常表现为双侧胸腔积液、严重呼吸窘迫、呼吸急促和 青紫,提示压迫对肺顺应性和气体交换障碍的机械性影响 在肺泡里。尽管Bartloet医生将胸膜腔内乳糜液的积聚确定为淋巴异常 在1633年,它们的形成和处理机制还没有完全确定。最近的研究表明, 产前淋巴功能需要排出胸腔积液,促进出生时肺充盈, 是生存所必需的。为了做到这一点,胸膜内广泛的淋巴管网络, 肋间间隙、小动脉和小静脉的血管周围间隙以及终末结缔组织。 呼吸性细支气管会维持体液平衡,促进有效的气体交换。异常扩张 其中被称为淋巴管扩张症的淋巴管通常与新生儿乳糜液有关, 肺未成熟,严重呼吸窘迫并死亡。即使鲁道夫·维肖博士描述了 1856年新生儿肺淋巴管扩张症的病因和治疗选择 仍然难以捉摸。我们的初步研究发现病理性MAPK激活之间存在意想不到的因果联系 以及小鼠和人类的淋巴管扩张。淋巴管MAPK的病理性激活导致重症肺 淋巴管扩张,乳酪在胸膜腔内堆积,并完全致死。初步分析了我国目前存在的 淋巴管扩张症患者的人体病理组织样本显示持续的MAPK 在淋巴管内皮细胞内激活,并概括了小鼠的表型。从机械上讲, 全基因组磷酸化MAPK占位筛选揭示了进化上保守的 淋巴管结构和功能所需的遗传程序。这项研究计划旨在确定如何 MAPK信号通路为淋巴管建立和维持一个特定的转录程序 发展。此外,拟议的研究将确定特定的激酶和 转录因子相互作用调节发育中肺组织中MAPK的染色质募集 淋巴管系统。所提出的一系列研究对于理解信号如何 与染色质修饰的转录因子相交的通路调节器官特异性的发育 淋巴血管系统,可高度适用于整个领域的先天性血管疾病。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Establishment and maintenance of blood-lymph separation.
血淋巴分离的建立和维持。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chinmay M Trivedi其他文献

Chinmay M Trivedi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chinmay M Trivedi', 18)}}的其他基金

Epigenetic regulation of lymphatic development
淋巴管发育的表观遗传调控
  • 批准号:
    10540097
  • 财政年份:
    2018
  • 资助金额:
    $ 60.97万
  • 项目类别:
Epigenetic regulation of lymphatic development
淋巴管发育的表观遗传调控
  • 批准号:
    10192805
  • 财政年份:
    2018
  • 资助金额:
    $ 60.97万
  • 项目类别:
Epigenetic regulation of lymphatic development
淋巴管发育的表观遗传调控
  • 批准号:
    9922367
  • 财政年份:
    2018
  • 资助金额:
    $ 60.97万
  • 项目类别:
Regulation of Cardiac Development by Chromatin Modifying Enzymes
染色质修饰酶对心脏发育的调节
  • 批准号:
    9045696
  • 财政年份:
    2013
  • 资助金额:
    $ 60.97万
  • 项目类别:
Regulation of Cardiac Development by Chromatin Modifying Enzymes
染色质修饰酶对心脏发育的调节
  • 批准号:
    8669159
  • 财政年份:
    2013
  • 资助金额:
    $ 60.97万
  • 项目类别:
Regulation of Cardiac Development by Chromatin Modifying Enzymes
染色质修饰酶对心脏发育的调节
  • 批准号:
    10399458
  • 财政年份:
    2013
  • 资助金额:
    $ 60.97万
  • 项目类别:
Regulation of Cardiac Development by Chromatin Modifying Enzymes
染色质修饰酶对心脏发育的调节
  • 批准号:
    8479285
  • 财政年份:
    2013
  • 资助金额:
    $ 60.97万
  • 项目类别:
Regulation of Cardiac Development by Chromatin Modifying Enzymes
染色质修饰酶对心脏发育的调节
  • 批准号:
    9251882
  • 财政年份:
    2013
  • 资助金额:
    $ 60.97万
  • 项目类别:
Hdac2 and Hopx: Regulators of Cardiac Development
Hdac2 和 Hopx:心脏发育的调节因子
  • 批准号:
    8307117
  • 财政年份:
    2011
  • 资助金额:
    $ 60.97万
  • 项目类别:
Hdac2 and Hopx: Regulators of Cardiac Development
Hdac2 和 Hopx:心脏发育的调节因子
  • 批准号:
    8316199
  • 财政年份:
    2011
  • 资助金额:
    $ 60.97万
  • 项目类别:

相似海外基金

Reverse Engineering the Alveolus: From cellular to microenvironment specification during development
对肺泡进行逆向工程:从开发过程中的细胞规范到微环境规范
  • 批准号:
    10534378
  • 财政年份:
    2022
  • 资助金额:
    $ 60.97万
  • 项目类别:
Alveolus as Incubator: Functional Genomic Dissection of the Host Response to SARS-CoV-2 Infection.
肺泡作为孵化器:宿主对 SARS-CoV-2 感染反应的功能基因组解剖。
  • 批准号:
    10245986
  • 财政年份:
    2021
  • 资助金额:
    $ 60.97万
  • 项目类别:
Reverse Engineering the Alveolus: From cellular to microenvironment specification during development
对肺泡进行逆向工程:从开发过程中的细胞规范到微环境规范
  • 批准号:
    10215602
  • 财政年份:
    2019
  • 资助金额:
    $ 60.97万
  • 项目类别:
Wnt-mediated epithelial-endothelial crosstalk in the generation and regeneration of the lung alveolus
Wnt介导的上皮-内皮串扰在肺泡生成和再生中的作用
  • 批准号:
    10326831
  • 财政年份:
    2018
  • 资助金额:
    $ 60.97万
  • 项目类别:
The influence that the influence of the different exercise length, the neuromuscular electrical stimulation (NMES) in skeletal muscle, Vitamin C intake and exercise on alveolus and cytokine
不同运动时长、骨骼肌神经肌肉电刺激(NMES)、维生素C摄入和运动对肺泡和细胞因子的影响
  • 批准号:
    18K10751
  • 财政年份:
    2018
  • 资助金额:
    $ 60.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A bovine alveolus model to replace cattle in the study of host-pathogen interactions in bovine tuberculosis
牛肺泡模型替代牛用于牛结核病宿主与病原体相互作用的研究
  • 批准号:
    NC/M002047/1
  • 财政年份:
    2016
  • 资助金额:
    $ 60.97万
  • 项目类别:
    Research Grant
Reverse Engineering the Alveolus: From cellular to microenvironment specification during development
对肺泡进行逆向工程:从开发过程中的细胞规范到微环境规范
  • 批准号:
    9223730
  • 财政年份:
    2016
  • 资助金额:
    $ 60.97万
  • 项目类别:
Bone augmentation of jaw and alveolus bone with coral block in preprosthetic surgery.
在假体前手术中用珊瑚块增强颌骨和牙槽骨。
  • 批准号:
    23592909
  • 财政年份:
    2011
  • 资助金额:
    $ 60.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
EXPRESSION AND FUNCTION OF CEACAM6 IN THE ALVEOLUS
CEACAM6 在肺泡中的表达和功能
  • 批准号:
    8054534
  • 财政年份:
    2011
  • 资助金额:
    $ 60.97万
  • 项目类别:
The novel therapeutic approach for emphysema by regeneration of microvessel and alveolus after intrapulmonary arterial administration of gelatin microspheres slowly releasing basic fibroblast growth factor(bFGF-GMS).
肺动脉内给予缓慢释放碱性成纤维细胞生长因子(bFGF-GMS)的明胶微球后,通过再生微血管和肺泡来治疗肺气肿的新方法。
  • 批准号:
    21390393
  • 财政年份:
    2009
  • 资助金额:
    $ 60.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了